Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AusperBio Reports on Antisense Oligonucleotide that Targets HBV mRNA

publication date: Jul 8, 2024

AusperBio, a Hangzhou-Boston biotech, reported its lead drug, an unconjugated antisense oligonucleotide (ASO) that targets all HBV mRNA, has now treated 193 participants in global and China clinical trials. The patient base includes 101 participants with chronic HBV. AHB-137 is designed to trigger the degradation of all HBV RN. The candidate is a novel unconjugated antisense oligonucleotide (ASO) with a dual mechanism the could become a backbone for novel therapies that aim to find a functional cure for CHB. The novel ASO is currently in a global Phase Ib trial and a Phase II trial in China. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital